Filì M, Trocme E, Herrspiegel C, et al. - Given that episcleral brachytherapy is the most common treatment for medium-sized choroidal melanomas, researchers conducted this investigation to analyze the impact of plaque brachytherapy dose and dose rate on risk for disease-related mortality in individuals with choroidal melanoma. The sample consisted of 1,238 patients who received ruthenium-106 or iodine-125 brachytherapy for choroidal melanoma at St. Erik Eye Hospital 1996 to 2016. At the tumour apex, the average radiation exposure ranged from 73.0 Gy in the first decile to 108.6 Gy in the tenth. After brachytherapy with decreasing doses between 108.6 and 73.0 Gy, or with decreasing dose rates between 2.8 and 0.5 Gy/hour, there are no increased hazards for choroidal melanoma related mortality.